Dimerix is discovering and developing important new drug therapies for major unmet medical needs identified using our proprietary cell-based drug discovery platform.

At the same time, our transformative drug discovery technology, known as Receptor-HIT, provides Dimerix with ongoing revenues from global industry partners seeking to improve their own programs.

Our vision is to positively improve human health through the creation of new treatments for major unmet medical needs.

Latest ASX Announcements

Corporate presentation

To view the presentation from BIO CEO & Investor conference click here

Dimerix Newsletter February 2017

Read our newsletter here. 

Dimerix key patent allowed in Japan

Read about this here. 

Dimerix Raises $2 million to Advance Clinical Program

Read the release here. 

Read More

Media Coverage

Corporate presentation November 2016

To view our most recent presentation please click here

NDF Research: Favourable Interim Data with DMX-200

To read report please click here

Read More

Stock Quote

View stock price: ASX Stock Price

Email Alert

subscribe to news updates